In silico and in vitro studies reveal Spondias metabolites as potential MAO-A inhibitors, suggesting novel therapeutic options for depression.
This study explores potential monoamine oxidase A (MAO-A) inhibitors from secondary metabolites of Spondias species for the treatment of depression. Using molecular docking, the interaction affinity and binding mode of the compounds with the active site of MAO-A were analyzed. Of the 104 metabolites identified, 78 showed significant interactions, with high affinity and specificity. Evaluation of the drug-like properties, according to Lipinski’s Rule of Five (molecular mass, hydrogen bond donors and acceptors and log P coefficient), showed that the majority met the criteria, suggesting good potential as drug candidates. Toxicity predictions were also carried out to ensure the safety of the compounds. In vitro MAO-A inhibition tests with ethanolic extracts of the species with the best docking performance indicated that Spondias metabolites are promising for new treatments for depression.
No takes yet. Share an insight, caveat, or question.
Medeiros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: